Sugi Predict

Sugi Predict / Compounds / SCHEMBL83748

SCHEMBL83748

SCHEMBL83748

OC[C@@H](F)CN(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PNP P00491 2/20 0.43
▸ HTT P42858 1/20 0.42
▸ TSHR P16473 3/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ GAA P10253 2/20 0.41
▸ NPBWR1 P48145 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ MCHR1 Q99705 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ CNR2 P34972 1/20 0.38
▸ OPRM1 P35372 1/20 0.38
▸ OPRD1 P41143 1/20 0.38
▸ OPRK1 P41145 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ MMP1 P03956 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3439186 1.00 PNP (0.43) PNPHTTTSHRKMT2AGAA
SCHEMBL13657504 1.00 PNP (0.43) PNPHTTTSHRKMT2AGAA
SCHEMBL6251771 0.88 ALDH1A1 (0.44) HTTTSHRKMT2AMCHR1MEN1
SCHEMBL29057663 0.85 AOC3 (0.41) HTTTSHRKMT2AMEN1ALDH1A1
SCHEMBL28586963 0.82 ALDH1A1 (0.40) HTTTSHRKMT2AMCHR1MEN1
SCHEMBL12881360 0.82 SLC6A2 (0.44) HTTTSHRALDH1A1KDM4ECNR2
SCHEMBL4151871 0.81 DNM1 (0.47) TSHRKMT2AMEN1ALDH1A1KDM4E
SCHEMBL10315714 0.81 KDM4E (0.46) TSHRMCHR1ALDH1A1POLBKDM4E
SCHEMBL19138243 0.80 TDP1 (0.39) PNPTSHRNPSR1MCHR1ALDH1A1
SCHEMBL19138242 0.80 TDP1 (0.39) PNPTSHRNPSR1MCHR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-3914435-B2 — — 2007-05-16 — — JP claimed
US-7034176-B2 Aminopropylphosphinic acids ASTRAZENECA AB (SE) 2006-04-25 — — US claimed
US-20030220303-A1 New aminopropylphosphinic acids ELEBRING THOMAS (SE) 2003-11-27 — — US claimed
US-6596711-B1 GABA B receptor agonists for use in the treatment of CNS disorders, such as muscle relaxation in spinal spasticity, cardiovascular disorders, asthma, gut motility disorders such as irritable bowel syndrome and gastroesophogeal reflux ASTRAZENECA AB (SE) 2003-07-22 — — US claimed
JP-2003516407-A — — 2003-05-13 — — JP claimed
CN-1413104-A New (aminopropyl) methylphosphinic acids ASTRAZENECA AB (SE) 2003-04-23 — — CN claimed
CN-1409716-A New amino propylphosphinic acid ASTRAZENECA AB (SE) 2003-04-09 — — CN claimed
US-20020156053-A1 New aminopropylphosphinic acids GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT 2002-10-24 — — US claimed
EP-1240172-A1 NEW AMINOPROPYLPHOSPHINIC ACIDS AstraZeneca AB (SE) 2002-09-18 — — EP claimed
WO-2001042252-A1 NEW AMINOPROPYLPHOSPHINIC ACIDS ASTRAZENECA AB (SE) 2001-06-14 — — WO claimed
US-20260146037-A1 PEPTIDYL NITRILE COMPOUND AND USE THEREOF SHANGHAI YIDIAN PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD (CN) 2026-05-28 — — US disclosed
US-12390463-B2 Dosage forms and regimens for amino acid compounds PLIANT THERAPEUTICS, INC. (US) 2025-08-19 — — US disclosed
US-20250223288-A1 AMINO ACID COMPOUNDS AND METHODS OF USE PLIANT THERAPEUTICS, INC. 2025-07-10 — — US disclosed
CN-120091811-A Integrin inhibitors and their use in combination with other agents 普利安特治疗公司 2025-06-03 — — CN disclosed
EP-4551204-A2 INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS Pliant Therapeutics, Inc. (US) 2025-05-14 — — EP disclosed
US-20020156053-A1 New aminopropylphosphinic acids GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT 2002-10-24 — — US disclosed
EP-1240172-A1 NEW AMINOPROPYLPHOSPHINIC ACIDS AstraZeneca AB (SE) 2002-09-18 — — EP disclosed
EP-1239843-A1 NEW (AMINOPROPYL)METHYLPHOSPHINIC ACIDS AstraZeneca AB (SE) 2002-09-18 — — EP disclosed
WO-2001042252-A1 NEW AMINOPROPYLPHOSPHINIC ACIDS ASTRAZENECA AB (SE) 2001-06-14 — — WO disclosed
WO-2001041743-A1 NEW (AMINOPROPYL)METHYLPHOSPHINIC ACIDS ASTRAZENECA AB (SE) 2001-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220303-A1 New aminopropylphosphinic acids GABRP, GABRB1, GABRA1 PNP 1038/4885HTT 2833/4885TSHR 1271/4885
US-12390463-B2 Dosage forms and regimens for amino acid compounds ITGB6, ITGA6, ITGAV PNP 2374/4885HTT 4359/4885TSHR 2610/4885
US-20020156053-A1 New aminopropylphosphinic acids GABRP, GABRB1, GABRA1 PNP 1038/4885HTT 2833/4885TSHR 1271/4885
US-20250223288-A1 AMINO ACID COMPOUNDS AND METHODS OF USE ITGB6, ITGA6, ITGA5 PNP 2066/4885HTT 4570/4885TSHR 3026/4885
US-20260146037-A1 PEPTIDYL NITRILE COMPOUND AND USE THEREOF JAK1, CTSZ, CTSL PNP 1680/4885HTT 2895/4885TSHR 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.